News
Donnerstag, 30.05.2019
New LIED publications in 2020
Anti-neonatal Fc Receptor (FcRn) Antibody Treatment Ameliorates Experimental Epidermolysis Bullosa Acquisita in Mice
Freitag, 17.05.2019
GRK1727 Spring Retreat 2020
The Spring Retreat 2020 will take place on April 28th on the campus in Lübeck.
Donnerstag, 21.02.2019
New LIED publications
Kasprick A, Bieber K, Ludwig RJ. Drug Discovery for Pemphigoid Diseases. Curr Protoc Pharmacol. 2019 Feb 20:e55. doi: 10.1002/cpph.55
Koga H, Prost-Squarcioni C, Iwata H, Jonkman MF, Ludwig RJ,...
Mittwoch, 21.11.2018
GRK1727 Autumn Retreat 2019
The Autumn Retreat 2019 is scheduled on November 7 and 8 (Thursday and Friday) and will take place in the Vitalia hotel in Bad Segeberg.
Dienstag, 04.09.2018
New LIED publication:
Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients
Mittwoch, 04.07.2018
LIED researchers together with Allmiral discover novel therapeutic target in EBA
Results published in Frontiers in Immunology: Therapeutic effect of a novel PI3Kδ inhibitor in experimental epidermolysis bullosa acquisita...
Donnerstag, 14.06.2018
New publications
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018 Apr 10;24(4):526 PMID: 29634689
Low-level mitochondrial heteroplasmy modulates DNA replication, glucose metabolism and...
